NEW YORK – Genetron Health announced Thursday a strategic partnership with Thermo Fisher Scientific to commercialize next-generation sequencing-based diagnostics in China.
The deal will bring the Genetron S5, which is based on Thermo Fisher's Ion GeneStudio S5 instrument for targeted NGS, to China's public hospitals for use in cancer diagnostics, genetic disease diagnosis, microbial testing, and reproductive health testing, among other uses.
"Thermo Fisher's memorandum of understanding with Genetron in this field will help further our companies' work together to develop in vitro diagnostic solutions for the fast-growing Chinese market," Tony Acciarito, president of Thermo Fisher Scientific China, said in a statement.
The Genetron S5 received China National Medical Products Administration approval in December 2019.
Beijing-based Genetron has also obtained NMPA approval for the Genetron S2000, a high-throughput sequencer that can obtain up to 1,400 Gb per run, as well as several cancer panels.
In May, Genetron signed a deal with Darui to develop sequencing tests for pathogen detection.